Navigation Links
Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
Date:8/8/2008

SAN DIEGO, Aug. 8 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today reported financial results for the three and six months ended June 30, 2008.

"As we've previously stated, we continue to increase our focus and resources on our proprietary programs that target large markets. Now we are beginning to see tangible results of that effort. Data from recent presentations at medical conferences validates the strength of our technology platform across multiple therapeutic areas," said Jonathan Lim, MD, President and CEO of Halozyme. "For example, Phase I clinical results showed faster absorption and onset for insulin when co-administered with our PH20 enzyme, a profile more similar to the body's own natural insulin. This could lead to the development of a best-in-class product. We have also demonstrated in animal models significant tumor suppression for PEGPH20 plus chemotherapy and controlled degradation of a structural component of the skin with HTI-501 that may prove beneficial in various dermatologic conditions. Over the next six months, we plan to initiate additional clinical trials to enhance the value of our pipeline."

Recent Scientific Achievements

-- Presentation of Phase I clinical results from the Company's diabetes

mellitus program at the American Diabetes Association's 68th Scientific

Sessions. The data showed that combining the Company's proprietary

recombinant human hyaluronidase enzyme (rHuPH20) with Humulin R(R)

(regular insulin human) or Humalog(R) (insulin lispro) yielded

pharmacokinetics and glucodynamics that better mimicked
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
2. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
3. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
4. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
5. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
8. Halozyme Therapeutics Amends Stockholder Rights Plan
9. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
10. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
11. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014 ... analyze and research medicinal plants and therapeutic derivatives ... industry, health professionals, and researchers about the challenges ... (Logo: http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility ... of Product Strategy. In this role, Michelle will work with ... guide in the development of iLab products. Her main goal ... benefit to the scientific community by offering the most advanced, ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... ) and sales and operations planning ( S&OP ) service, ... Biomanufacturing Summit , which will be held at the Hilton ... conference, join Kinaxis customer Elisabeth Kaszas , Director of ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... PharmaVentures announced today that it was delighted ... deal which won Scrip,s ,Outsourcing Deal of the Year 2011,. ... it was "one the largest and most comprehensive R&D alliances ... terms of the agreement, Sanofi retains access to some of ...
... BETHESDA, Md., Jan. 11, 2012   Spherix Incorporated (NASDAQ: ... therapy in diabetes, metabolic syndrome and atherosclerosis, and ... food, supplement, biotechnology and pharmaceutical companies, today reported ... study of its drug candidate, SPX-106.  Results demonstrated ...
... Calif., Jan. 11, 2012 IndustryWeek magazine today ... LIFE ) plant in Austin, Texas, one of its Top ... first biotechnology facility to win the prestigious award.  IndustryWeek ... improvement in gross margins since 2007; 94% error reduction in ...
Cached Biology Technology:PharmaVentures' Client Sanofi Wins Scrip 'Outsourcing Deal of the Year Award' 2Spherix Announces Successful Completion of Important Toxicology Study of SPX-106 2Spherix Announces Successful Completion of Important Toxicology Study of SPX-106 3Life Technologies Plant in Austin, Texas Named One of IndustryWeek's Top Ten Best Plants for 2011 2Life Technologies Plant in Austin, Texas Named One of IndustryWeek's Top Ten Best Plants for 2011 3Life Technologies Plant in Austin, Texas Named One of IndustryWeek's Top Ten Best Plants for 2011 4
(Date:4/17/2014)... study suggests that fish consumption advisories for expecting ... long-lived contaminants like persistent organic pollutants (POPs). ... researchers including University of Toronto Scarborough PhD student ... how different levels of environmental contamination, a mother,s ... in the body influenced exposure in her children. ...
(Date:4/17/2014)... Kansas State University engineer has developed a patented ... improvised explosive devices. The same technique could help ... Steven M. and Kay L. Theede chair in ... engineering, and his research team have created a ... in car trunks. The distance detection method ...
(Date:4/17/2014)... and pathogens that devastate honeybees in Europe, Asia and ... do not appear to be impacting native honeybee populations ... researchers., The invasive pests include including Nosema microsporidia ... honeybees appear to be resilient to these invasive pests, ... control pests in Europe, Asia and the United States ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Patented research remotely detects nitrogen-rich explosives 2East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
... have identified a relationship between two proteins in the brain ... finding has led to speculation that existing drugs used to ... therapies to alleviate the symptoms of autism. The discovery ... neurexin-1 gene, which is located in brain cells and assists ...
... team of researchers led by North Carolina State University has ... Puerto Rico,s most remarkable ecosystems by conducting the first comprehensive ... Thomas Kwak, who led the study, says many of these ... calls the research "a huge first step in conserving and ...
... human civilisation was the practice of sustainable agriculture. But we ... for over 50 million years. Just as farming helped humans ... become dominant herbivores, and one of the most successful social ... issue of Microbiology Today, leaf-cutter ants have developed a system ...
Cached Biology News:Researchers find link between nicotine addiction and autism 2Researchers find link between nicotine addiction and autism 3NC State takes research lead in protecting Puerto Rico's unique freshwater fisheries 2Farming and chemical warfare: A day in the life of an ant? 2Farming and chemical warfare: A day in the life of an ant? 3
WD-repeat protein 4...
... Cultured human omental ... obese but otherwise healthy ... availability of diabetic cells. ... information. Support media also ...
11-keto Testosterone EIA Antiserum hormones steroids antisera antiserum eias enzyme immunoassays reagents 11-keto-testosterone...
Chaps Cell Extract Buffer can be used to lyse cells under nondenaturing conditions and is recommendedfor the preparation of cell lysates to be used with our caspase signaling pathway antibodies...
Biology Products: